Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know

Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00.

Shares of CRISPR Therapeutics are trading down 8.24% over the last 24 hours, at $59.34 per share.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.